AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q116808

U.S. Patent Appln. No.: 10/568,761

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1-18. (canceled).

19. (currently amended): A method for improving or treating of inflammatory

bowel disease (IBD) comprising administering a therapeutic agent comprising an effective

amount of anti-CD-81 antibody to a patient in need thereof.

20. (previously presented): The method according to claim 19, wherein the anti-

CD81 antibody is a monoclonal antibody.

21-30. (canceled).

31. (previously presented): The method of claim 19, in which the antibody is

provided in the form of a Fab, F(ab')2, Fv or single-chain Fv.

32. (previously presented): The method of claim 19, wherein the patient in need

thereof is suffering from IBD associated with shortening of the intestinal length and wherein the

shortened intestinal length is improved or treated by the method.

2

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q116808

U.S. Patent Appln. No.: 10/568,761

33. (previously presented): The method of claim 19 wherein the effective amount is

0.0001 mg to 1000 mg per kilogram of the body weight of the patient for one administration.

34. (previously presented): The method of claim 19 wherein the effective amount is

several milligrams to 2 g per day.

35. (previously presented): The method of claim 19, wherein the patient in need

thereof is suffering from IBD associated with loose stool or diarrhea and wherein the loose stool

or diarrhea is improved or treated by the method.

36. (new): A method for improving or treating inflammatory bowel disease (IBD)

associated with shortening of intestinal length, comprising administering a therapeutic agent

comprising an effective amount of anti-CD-81 antibody to a patient in need thereof.

37. (new): A method for improving or treating inflammatory bowel disease (IBD)

associated with loose stool or diarrhea, comprising administering a therapeutic agent comprising

an effective amount of anti-CD-81 antibody to a patient in need thereof.

3